GlassScriptPhysician profile
Jonathan D Aspinwall
NPI 1063804722
$7,265.63
in general payments reported to CMS, 2019-2025
44 companies · $1,040 in 2025
The $1,040 reported for 2025 was more than what 88% of Acute Care (Nurse Practitioner) providers received nationally (typical 2025 total: $151).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,389 · 2022: $1,981 · 2023: $1,540 · 2024: $1,315 · 2025: $1,040.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,895.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,894.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,953.24 | 2021-2025 | Rybelsus, Ozempic, Wegovy |
| Amgen INC. | $600.47 | 2021-2025 | Repatha, Otezla, Prolia |
| Abbvie INC. | $597.01 | 2021-2025 | |
| Glaxosmithkline, LLC. | $505.51 | 2021-2024 | Trelegy Ellipta, Shingrix, Arexvy |
| Lilly USA, LLC | $428.30 | 2021-2024 | Mounjaro, Jardiance, Zepbound |
| Sanofi-Aventis U.S. LLC | $336.42 | 2021-2023 | |
| Dexcom, INC. | $316.93 | 2021-2025 | Dexcom G6 Transmitter |
| Pfizer INC. | $308.05 | 2021-2025 | |
| Astrazeneca Pharmaceuticals LP | $232.27 | 2021-2025 | Farxiga, Airsupra |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $175.90 | 2023-2025 | Xifaxan, Trulance |
| Exact Sciences Corporation | $173.15 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Eisai INC. | $169.58 | 2021-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $154.67 | 2021-2025 | Jardiance |
| Idorsia Pharmaceuticals US INC | $109.16 | 2022-2023 | Quviviq |
| Novartis Pharmaceuticals Corporation | $107.74 | 2022-2025 |
Show all 44 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jonathan Aspinwall listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.